Biophan explodiert nach TOP News ! - 500 Beiträge pro Seite

[Matheros]

WKN: 541861
Symbol: BTN

Hohe Umsätze in Frankfurt !

Biophan Releases Positive Animal Study on MYO-VAD(TM)


2006-12-14 08:33 ET - News Release

Data Indicates Promise for Treatment of Heart Failure


Company Website: http://www.biophan.com
ROCHESTER, N.Y. -- (Business Wire)

Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, in conjunction with MYOTECH, LLC, recently presented results of animal studies that indicate the potential of the MYO-VAD cardiac support system to significantly improve the treatment of heart failure. This devastating disease currently has no cure and affects an estimated 5,000,000 Americans each year.

Heart failure is a progressive condition that involves the heart re-shaping, or “remodeling”, into a less effective blood pump. This occurs after the heart has been damaged by any disease or condition that puts extra stress on the heart’s muscle or deprives it of blood. High blood pressure, coronary artery disease and heart attacks are typical causes. For example, within 6 years of a recognized heart attack 22% of men and 46% of women will be disabled with heart failure, according to the American Heart Association.

The animal study presented at the recent Cleveland Clinic symposium on heart failure suggests that the MYO-VAD can significantly improve the ability of failing hearts to pump blood, while simultaneously reducing the stress on the heart that accounts for the vicious, progressive cycle of heart failure.

Researchers found that key biomarkers of heart failure increased in animal hearts with induced heart damage, but decreased in animals whose damaged hearts were supported with the MYO-VAD. Investigators concluded that the device “can significantly augment the failing heart while reducing myocardial stress,” and that the device “can provide adequate hemodynamic support while favorably altering the maladaptive pathophysiology of heart failure.”

According to the American Heart Association, 550,000 new cases of heart failure are diagnosed annually in the U.S. and an estimated 15 million new cases are reported yearly worldwide. Direct and indirect costs of heart failure in the U.S. in 2006 have been estimated at $29 billion.

“Heart failure is most commonly treated with pharmaceuticals, but this approach is ineffective and heart failure remains the number one killer and the most costly condition for the U.S. health care system,” said Jeffrey Helfer, President of Biophan’s Cardiovascular Division.

According to Mr. Helfer, “The MYO-VAD technology has already demonstrated its ability to support suddenly failing hearts (such as in a heart attack). By favorably altering the progression of heart failure that follows, we believe these results indicate potential for the MYO-VAD to treat a much wider range of patient conditions.”

The scientific presentation can be found on the company website at www.biophan.com/myovad_results1206

About the MYO-VAD

The MYO-VAD can be implanted on an arrested or weak heart in approximately three minutes, restoring cardiac output. It consists of a flexible polymer cup that fits around the heart, compressing and expanding both ventricles. Because it does not come into contact with circulating blood, the MYO-VAD promises to eliminate the serious and potentially fatal complications of clotting and stroke, bleeding, and infection that plague all other Ventricular Assist Devices (VADs).

Due to its technically simple installation and removal requirements, anticipated lower rates of patient complications, and lower device cost, the MYO-VAD is expected to provide a significant reduction in the cost of treating heart failure patients. This promises to extend the physician’s ability to treat heart failure and help save thousands of lives.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company licenses its technologies which improve the MRI safety and image compatibility of medical devices to leading device manufacturers. In addition, the Company is commercializing the MYOTECH MYO-VAD(TM), a new, cardiac support system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contacts:

The Investor Relations Group, Inc.
Investors:
Daniel Berg/James Carbonara, 212-825-3210
or
Media:
Janet Vasquez/Lynn E. Granito, 212-825-3210

Source: Biophan Technologies, Inc.

[ChristianLandman]

Du und deine Explosionen. Deine ID sollte mal explodieren das man nicht immer solche Threads sich anschauen muss.

Im Nachbarboard bist du auch schon bekannt für deine Explosionen die meist nur kurz nach oben zucken bevor sie ins Minus laufen.

[Broker_Hans]

Antwort auf Beitrag Nr.: 26.175.264 von Matheros am 14.12.06 14:48:13

Wo explodiert sie denn ???

[Bienenvater]

hm...ist wohl so laut explodiert, dass mir das Trommelfell geplatzt ist.
Deshalb habe ich den Knall wohl nicht gehört.

[naschu72.]

Jenau "BIPH" ist am explodieren

[cienfuego]

ist doch schön, wenn sich noch jemand freuen kann!
Genau diese Einsteiger brauchen wir dringend bei dem Suuper-
Einstiegsniveau! - Denn an die Aktie glauben wir doch noch alle!
cf

[nazim4]

Antwort auf Beitrag Nr.: 26.175.264 von Matheros am 14.12.06 14:48:13

Na danke, durch deinen "explosiven" Beitrag weiß ich nun, daß Biophan mit Tierversuchen arbeitet. Noch ein Grund mehr, diesen Müll nicht zu kaufen.
Wieso heißt es eigentlich Biotechnologie, wenn Tierversuche doch noch nötig sind?